Targeting the renin–angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

Bibliography

• COLLINS R, PETO R, MACMAHON S et al.: Blood pressure, stroke, and coronary heart disease. Lancet (1990) 335:827–838.
   PubMed Web of Science ®Google Scholar
• MACMAHON S, RODGERS A: Blood pressure, antihypertensive treatment and stroke risk. J. Hypertens. Suppl. (1994) 12:S5–S14.
   PubMedGoogle Scholar
• HANSSON L, ZANCHETTI A,CARRUTHERS SG et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• CHOBANIAN AV BAKRIS GL,BLACK HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 289:2560–2572.
   PubMed Web of Science ®Google Scholar
• EUROPEAN SOCIETY OFHYPERTENSION-EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES COMMITTEE: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011–1053.
   PubMed Web of Science ®Google Scholar
• DZAU VJ: Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension (2001) 37:1047–1052.
   PubMed Web of Science ®Google Scholar
• KEARNEY PM, WHELTON M, REYNOLDS K, MUNTNER P, WHELTON PK, HE J: Global burden of hypertension: analysis of worldwide data. Lancet (2005) 365:217–223.
   PubMed Web of Science ®Google Scholar
• HAJJAR I, KOTCHEN TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988— 2000. JAMA (2003) 290:199–206.
   PubMed Web of Science ®Google Scholar
• BURT VI,, WHELTON P, ROCCELLA EJ et al.: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988— 1991. Hypertension (1995) 25:305–313.
   PubMed Web of Science ®Google Scholar
• WOLF-MATER K, COOPER RS, BANEGAS JR et al.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA (2003) 289:2363–2369.
   PubMed Web of Science ®Google Scholar
• KANNEL WB: Framingham study insightsinto hypertensive risk of cardiovascular disease. Hypertens. Res. (1995) 18:181–196.
   PubMedGoogle Scholar
• NO AUTHORS LISTED: Effects oftreatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA (1967) 202:1028–1034.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, LINDHOLM LH, HANSSON L, SCHERSTEN B, EKBOM T, WESTER PO: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet (1991) 338: 1281–1285.
   Google Scholar
• COOPE J, WARRENDER TS: Randomised trial of treatment of hypertension in elderly patients in primary care. Br. Med. J. (Clin. Res. Ed) (1986) 293:1145–1151.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ (1992) 304:405–412.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISDTED: MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br. Med. J. (Clin. Res. Ed.) (1985) 291:97–104.
   PubMed Web of Science ®Google Scholar
• HELGELAND A: Treatment of mildhypertension: a five year controlled drug trial. The Oslo study. Am. J. Med. (1980) 69:725–732.
   PubMed Web of Science ®Google Scholar
• HANSSON L, LINDHOLM LH, EKBOM T et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 354:1751–1756.
   PubMed Web of Science ®Google Scholar
• HANSSON L, LINDHOLM LH, NISKANEN L et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 353:611–616.
   PubMed Web of Science ®Google Scholar
• HANSSON L, HEDNER T, LUND-JOHANSEN P et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet (2000) 356:359–365.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program cooperative group. JAMA (1979) 23:2562–2571.
   Google Scholar
• NO AUTHORS LISTED: Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program cooperative group. JAMA (1979) 242:2572–2577.
   PubMed Web of Science ®Google Scholar
• AMERY A, BIRKENHAGER W, BRIXKO P et al.: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet (1985) 1: 1349–1354.
   Google Scholar
• NO AUTHORS LISTED: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA (1970) 213:1143–1152.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. /AMA (1991) 265:3255–3264.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, FAGARD R, THUS L et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 350:757–764.
   PubMed Web of Science ®Google Scholar
• LIU L, WANG JG, GONG L, LIU G, STAESSEN JA: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J. Hypertens. (1998) 16:1823–1829.
   PubMed Web of Science ®Google Scholar
• KJELDSEN SE, DAHLOF B, DEVEREUX RB et al.: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA (2002) 288:1491–1498.
   PubMed Web of Science ®Google Scholar
• TURNBULL F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet (2003) 362:1527–1535.
   PubMed Web of Science ®Google Scholar
• THUS L, FAGARD R, LUNEN P, STAESSEN J, VAN HOOF R, AMERY A: A meta-analysis of outcome trials in elderly hypertensives. J. Hypertens. (1992) 10:1103–1109.
   PubMed Web of Science ®Google Scholar
• NEAL B, MACMAHON S, CHAPMAN N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet (2000) 356:1955–1964.
   PubMed Web of Science ®Google Scholar
• KJELDSEN SE, JULIUS S, HEDNER T,HANSSON L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press. (2001) 10:190–192.
   PubMed Web of Science ®Google Scholar
• AMERICAN HEART ASSOCIATION: Heart Disease and Stroke Statistics-2005 Update. American Heart Association, Dallas, Texas, US (2005).
   Google Scholar
• MURRAY CJ, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 349:1498–1504.
   PubMed Web of Science ®Google Scholar
• AMOS AF, MCCARTY DJ, ZIMMET P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. (1997) 14\(Suppl. 5):S1–585.
   Google Scholar
• US RENAL DATA SYSTEM: USRDS 1998 Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, Maryland, USA (1998).
   Google Scholar
• PASTAN S, BAILEY J: Dialysis therapy. N Engl. J. Med. (1998) 338:1428–1437.
   PubMed Web of Science ®Google Scholar
• RUILOPE LM, COCA A, VOLPE M, WAEBER B: ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am. J. Hypertens. (2002) 15(4 Pt 0:367–371.
   PubMed Web of Science ®Google Scholar
• VOLPE M, RUILOPE LM, MCINNES GT, WAEBER B, WEBER Mk Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J. Hum. Hypertens. (2005) 19:331–339.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, WANG JG, THUS L: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. (2003) 21:1055–1076.
   PubMed Web of Science ®Google Scholar
• NISKANEN L, HEDNER T, HANSSON L, LANKE J, NIKLASON A: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/13-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care (2001) 24:2091–2096.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N EngL J. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• BOSCH J, YUSUF S, POGUE J et al.: Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 324:699–702.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet (2000) 355:253–259.
   PubMed Web of Science ®Google Scholar
• SLEIGHT P, YUSUF S, POGUE J, TSUYUKI R, DIAZ R, PROBSTFIELD J: Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2001) 358:2130–2131.
   PubMed Web of Science ®Google Scholar
• SVENSSON P, DE FAIRE U, SLEIGHT P,YUSUF S, OSTERGREN J: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension (2001) 38:E28–E32.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, DOMANSKI MJ, FOWLER SE et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N EngL J. Med. (2004) 351:2058–2068.
   PubMed Web of Science ®Google Scholar
• PROGRESS COLLABORATIVE GROUP: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 358(9287):1033–1041.
   PubMed Web of Science ®Google Scholar
• DAVIS BR, CUTLER JA, GORDON DJ et al.: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am. J. Hypertens. (1996) 9(4 Pt 1):342–360.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA (2000) 283:1967–1975.
   PubMed Web of Science ®Google Scholar
• ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). /AMA (2002) 288:2981–2997.
   PubMed Web of Science ®Google Scholar
• WING LM, REID CM, RYAN P et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N EngL J. Med. (2003) 348:583–592.
   PubMed Web of Science ®Google Scholar
• FOX KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782–788.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995–1003.
   PubMed Web of Science ®Google Scholar
• IBSEN H, WACHTELL K, OLSEN MH et al.: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J. Hypertens. (2004) 22:1805–1811.
   PubMed Web of Science ®Google Scholar
• IBSEN H, OLSEN MH, WACHTELL K et al.: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 45:198–202.
   PubMed Web of Science ®Google Scholar
• LINDHOLM LH, IBSEN H, DAHLOF B et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:1004–1010.
   PubMed Web of Science ®Google Scholar
• WACHTELL K, LEHTO M, GERDTS E et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. J. Am. Coll. CardioL (2005) 45:712–719.
   PubMed Web of Science ®Google Scholar
• WACHTELL K, HORNESTAM B, LEHTO M et al.: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study./ Am Coll. Cardiol. (2005) 45:705–711.
   PubMed Web of Science ®Google Scholar
• LITHELL H, HANSSON L, SKOOG I et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. (2003) 21:875–886.
   PubMed Web of Science ®Google Scholar
• KILANDER L, NYMAN H, BOBERG M, HANSSON L, LITHELL H: Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension (1998) 31:780–786.
   PubMed Web of Science ®Google Scholar
• JULIUS S, KJELDSEN SE, WEBER M et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 363:2022–2031.
   PubMed Web of Science ®Google Scholar
• WEBER MA, JULIUS S, KJELDSEN SE et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (2004) 363:2049–2051.
   PubMed Web of Science ®Google Scholar
• SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention. Principal Results of a Prospective Randomized Controlled Study (MOSES). Stroke (2005) 36:1218–1226.
   PubMed Web of Science ®Google Scholar
• TEO K, YUSUF S, SLEIGHT P et al.: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J. (2004) 148:52–61.
   PubMed Web of Science ®Google Scholar
• WILLIAMS B: Recent hypertension trials: implications and controversies. J. Am. Coll. CardioL (2005) 45:813–827.
   PubMed Web of Science ®Google Scholar
• EPSTEIN BJ, GUMS JG: Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann. Pharmacother. (2005) 39:470–480.
   PubMed Web of Science ®Google Scholar
• MCMURRAY JJ, PFEFFER MA, SWEDBERG K, DZAU VJ: Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation (2004) 110:3281–3288.
   PubMed Web of Science ®Google Scholar
• JORDE UP, ENNEZAT PV, LISKER J et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 101:844–846.
   PubMed Web of Science ®Google Scholar
• VERMA S, STRAUSS M: Angiotensin receptor blockers and myocardial infarction. BMJ (2004) 329:1248–1249.
   PubMed Web of Science ®Google Scholar
• LEE VC, RHEW DC, DYLAN M, BADAMGARAV E, BRAUNSTEIN GD, WEINGARTEN SR: Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann. Intern. Med. (2004) 141:693–704.
   PubMed Web of Science ®Google Scholar
• PAPADEMETRIOU V, FARSANG C, ELMFELDT D et al: Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. CardioL (2004) 44:1175–1180.
   PubMed Web of Science ®Google Scholar
• AMERICAN HEART ASSOCIATION: Heart Disease and Stroke Statistics -2004 Update. American Heart Association, Dallas, Texas, US (2003).
   Google Scholar
• VERMES E, TARDIF JC, BOURASSA MG et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation (2003) 107:2926–2931.
   PubMed Web of Science ®Google Scholar
• PEDERSEN OD, BAGGER H, KOBER L, TORP-PEDERSEN C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation (1999) 100:376–380.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, PFEFFER M, COEN-SOLAR A: Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from the CHARM study [abstract]." Am. Coll. CardioL (2004) 43(Suppl. A):222A.
   Web of Science ®Google Scholar
• MAGGIONI AP, LATINI R, CARSON PE et al.: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. (2005) 149:548–557.
   PubMed Web of Science ®Google Scholar
• WHO STUDY GROUP: Prevention of diabetes mellitus: report of WHO study group. WHO Tech Rep Set. (1994) 844:1–100.
   PubMed Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION AND NATIONAL INSTITUTE OF DIABETES, DIGESTIVE AND KIDNEY DISEASES: The prevention or delay of Type 2 diabetes. Diabetes Care (2002) 25:742–749.
   PubMed Web of Science ®Google Scholar
• GRESS TW, NIETO FJ, SHAHAR E, WOFFORD MR, BRANCATI FL: Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N EngL J. Med. (2000) 342:905–912.
   PubMed Web of Science ®Google Scholar
• VERDECCHIA P, REBOLDI G, ANGELI F et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 43:963–969.
   PubMed Web of Science ®Google Scholar
• PEPINE CJ, COOPER-DEHOFF RM: Cardiovascular therapies and risk for development of diabetes. J. Am. Coll. Cardiol. (2004) 44:509–512.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ: Renin-angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. (2004) 30:487–496.
   PubMed Web of Science ®Google Scholar
• PRISANT LM: Preventing Type II diabetes mellitus. J. Clin. PharmacoL (2004) 44:406–413.
   PubMed Web of Science ®Google Scholar
• HEALEY JS, MORILLO CA, CONNOLLY SJ: Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. Curr. Opin. CardioL (2005) 20:31–37.
   PubMed Web of Science ®Google Scholar
• BOURASSA MG: Angiotensin II inhibition and prevention of atrial fibrillation and stroke. J. Am. Coll. CardioL (2005) 45:720–721.
   PubMed Web of Science ®Google Scholar
• GOETTE A, ARNDT M, ROCKEN C et al.: Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation (2000) 101:2678–2681.
   PubMed Web of Science ®Google Scholar
• LID, SHINAGAWA K, PANG L et al.: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation (2001) 104:2608–2614.
   PubMed Web of Science ®Google Scholar
• SHI Y, LI D, TARDIF JC, NATTEL S: Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc. Res. (2002) 54:456–461.
   PubMed Web of Science ®Google Scholar
• VERDECCHIA P, REBOLDI G, GATTOBIGIO R et al.: Atrial fibrillation in hypertension: predictors and outcome. Hypertension (2003) 41:218–223.
   PubMed Web of Science ®Google Scholar
• VAZIRI SM, LARSON MG, BENJAMIN EJ, LEVY D: Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation (1994) 89:724–730.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, DAHLOF B, GERDTS E et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 110:1456–1462.
   PubMed Web of Science ®Google Scholar
• LEITER LA, LEWANCZUK RZ: Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am. J. Hypertens. (2005) 18:121–128.
   PubMed Web of Science ®Google Scholar
• JANDELEIT-DAHM KA, TIKELLIS C, REID CM, JOHNSTON CI, COOPER ME: Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. Hypertens. (2005) 23:463–473.
   Web of Science ®Google Scholar
• SCHEEN AJ: Renin-angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. (2004) 30:498–505.
   PubMed Web of Science ®Google Scholar
• SCHUPP M, JANKE J, CLASEN R, UNGER T, KINTSCHER U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-y activity. Circulation (2004) 109:2054–2057.
   PubMed Web of Science ®Google Scholar
• BENSON SC, PERSHADSINGH HA, HO CI et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARy-modulating activity. Hypertension (2004) 43:993–1002.
   PubMed Web of Science ®Google Scholar
• YAVUZ D, KOC M, TOPRAK A et al.: Effects of ACE inhibition and AT,-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J. Renin Angiotensin ALdosterone Syst. (2003) 4:197–203.
   PubMed Web of Science ®Google Scholar
• FOGARI R, ZOPPI A, LAZZARI P et al.:ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J. Cardiovasc. PharmacoL (1998) 32:616–620.
   PubMed Web of Science ®Google Scholar
• FOGARI R, ZOPPI A. CORRADI L, LAZZARI P, MUGELLINI A, LUSARDI P: Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br. J. Clin. PharmacoL (1998) 46:467–471.
   PubMed Web of Science ®Google Scholar
• OLSEN MH, FOSSUM E, HOIEGGEN A et al.: Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J. Hypertens. (2005) 23:891–898.
   PubMed Web of Science ®Google Scholar
• MOAN k RISANGER T, EIDE I, KJELDSEN SE: The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press. (1994) 3:185–188.
   PubMedGoogle Scholar
• PAOLISSO G, TAGLIAMONTE MR, GAMBARDELLA A et al.: Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J. Hum. Hypertens. (1997) 11:307–312.
   PubMed Web of Science ®Google Scholar
• ANAN F, TAKAHASHI N, OOIE T, HARA M, YOSHIMATSU H, SAIKAWAT: Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism (2004) 53:777–781.
   PubMed Web of Science ®Google Scholar
• MACMAHON S, NEAL B, RODGERS A: Hypertension-time to move on. Lancet (2005) 365:1108–1109.
   PubMed Web of Science ®Google Scholar
• MEDICAL EXPERTS REDEFINE HYPERTENSION [press release]: San Francisco American Society of Hypertension Twentieth Annual Scientific Meeting. San Francisco, US (2005).
   Google Scholar
• VERMES E, DUCHARME A, BOURASSA MG, LESSARD M, WHITE M, TARDIF JC: Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation (2003) 107:1291–1296.
   PubMed Web of Science ®Google Scholar
• LINDHOLM LH, PERSSON M, ALAUPOVIC P, CARLBERG B, SVENSSON A, SAMUELSSON 0: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens. (2003) 21: 1563–1574.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 362:759–766.
   PubMed Web of Science ®Google Scholar
• YUSUF S, PFEFFER MA, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 362:777–781.
   PubMed Web of Science ®Google Scholar
• MCMURRAY JJ, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767–771.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, MCMURRAY JJ, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772–776.
   PubMed Web of Science ®Google Scholar
• IMS Health, IMS MIDASTM, 2002 — 2004; MTA 4Q04. Affiliation
   Google Scholar